Improving Cognitive Function in AD Therapy Using a Combinatorial Approach of Reducing Disease Progression and Increasing Memory

About the Research Project
Program
Award Type
Postdoctoral Fellowship
Award Amount
$200,000
Active Dates
September 01, 2020 - November 30, 2022
Grant ID
A20201729F
Mentor(s)
Riqiang Yan, PhD, The Cleveland Clinic Foundation
Goals
Aβ is the main component of amyloid plaques found in the brains of Alzheimer patients. Production of Aβ is nearly stopped by inhibiting BACE1 enzyme. Therefore, BACE1 inhibitors are used to reduce Aβ production and amyloid deposition. But their use can lead to many side effects that impact learning and storage of memory. Therefore, it is critical to develop new therapeutic strategies. We propose to use BACE1 inhibitor drugs in combination with mGluR activator drugs. This combination therapy will stop the disease progression and help in memory retention at the same time. We will test our strategy in mice in the current study. Positive results from this study will provide Alzheimer patients a better quality of life.
Summary
Abnormal circulation of Abeta peptides in brain likely causes Alzheimer’s disease. Inhibition of BACE1, the enzyme that initiates Abeta production, is therefore being explored to treat AD patients. However clinically tested BACE1 inhibitors have failed to improve cognitive function despite strong reduction in Abeta generation. We observe BACE1 activity is essential for synaptic functions and ultimately cognitive abilities. Therefore, we explore molecular targets which can reverse synaptic impairments. One such candidate is mGluR PAM. We are developing treatment therapies combining BACE1 inhibitors for reducing amyloid deposition and mGluR PAM for countering synaptic deficits as a more effective approach for treating AD patients.
Grants
Related Grants
Alzheimer's Disease Research
Tau, Aβ, and Network Degeneration in Alzheimer’s Disease
Active Dates
July 01, 2014 - June 30, 2017
Principal Investigator
Rik Ossenkoppele, PhD
Tau, Aβ, and Network Degeneration in Alzheimer’s Disease
Active Dates
July 01, 2014 - June 30, 2017

Principal Investigator
Rik Ossenkoppele, PhD
Alzheimer's Disease Research
Fingerprinting In Vivo and In Vitro Prion Strains
Active Dates
September 01, 2020 - November 30, 2022
Principal Investigator
Hyunjun Yang, PhD
Fingerprinting In Vivo and In Vitro Prion Strains
Active Dates
September 01, 2020 - November 30, 2022

Principal Investigator
Hyunjun Yang, PhD
Alzheimer's Disease Research
Partnership with Molecular Neurodegeneration Open Access Journal
Active Dates
July 01, 2010 - June 30, 2015
Principal Investigator
Guojun Bu, PhD
Partnership with Molecular Neurodegeneration Open Access Journal
Active Dates
July 01, 2010 - June 30, 2015

Principal Investigator
Guojun Bu, PhD